利用国家肺癌筛查试验数据集个体化肺癌风险预测与影像随访建议
本研究基于国家肺癌筛查试验第一年筛查数据,按2005年Fleischner学会结节大小标准计算恶性风险,并加入吸烟包年、性别和结节位置进行风险分层。结果显示,男性、≥60包年且上叶>4且≤6 mm结节恶性风险为12.4%,显著高于同类大小结节均值3.81%(P<.0001);54%的>4且≤6 mm结节被重新分类为比Fleischner推荐更长期的随访,27%的≤4 mm结节被重新分类为更短期随访。
要点
- 结节大小与恶性风险的相关性与Fleischner学会推荐一致。
- 加入吸烟史、性别和结节位置可显著分层结节恶性风险。
- 基于个体化风险,部分结节随访建议较Fleischner推荐延长或缩短。
核心结论
- 纳入3个 demographic 数据点后,Fleischner分类内肺结节恶性风险可大幅分层,并可制定更个体化的随访建议。
研究设计与样本
- 数据驱动方法研究,使用国家肺癌筛查试验第一年筛查数据集,算法将结节分类为恶性或非恶性。
诊断标准与关键数值
- 结节恶性风险按2005年Fleischner学会推荐的大小标准计算,并结合吸烟包年、性别和结节位置。
- 影像随访建议按Fleischner大小类别的恶性风险分配。
- 男性、≥60包年、上叶>4且≤6 mm结节恶性风险12.4%,同类大小结节均值为3.81%(P<.0001)。
- 基于个体化恶性风险,54%的>4且≤6 mm结节被重新分类为比Fleischner推荐更长期的随访。
- 27%的≤4 mm结节被重新分类为更短期随访。
临床应用与阅片要点
- 利用国家肺癌筛查试验等现有临床数据集联合本地采集数据集,可帮助临床医生提供更个体化的恶性风险预测和随访建议。
- 阅片时可结合结节大小、吸烟包年、性别和结节位置综合评估恶性风险并调整随访建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To demonstrate a data-driven method for personalizing lung cancer risk prediction using a large clinical dataset.
MATERIALS AND METHODS: An algorithm was used to categorize nodules found in the first screening year of the National Lung Screening Trial as malignant or nonmalignant. Risk of malignancy for nodules was calculated based on size criteria according to the Fleischner Society recommendations from 2005, along with the additional discriminators of pack-years smoking history, sex, and nodule location. Imaging follow-up recommendations were assigned according to Fleischner size category malignancy risk.
RESULTS: Nodule size correlated with malignancy risk as predicted by the Fleischner Society recommendations. With the additional discriminators of smoking history, sex, and nodule location, significant risk stratification was observed. For example, men with ≥60 pack-years smoking history and upper lobe nodules measuring >4 and ≤6 mm demonstrated significantly increased risk of malignancy at 12.4% compared to the mean of 3.81% for similarly sized nodules (P < .0001). Based on personalized malignancy risk, 54% of nodules >4 and ≤6 mm were reclassified to longer-term follow-up than recommended by Fleischner. Twenty-seven percent of nodules ≤4 mm were reclassified to shorter-term follow-up.
DISCUSSION: Using available clinical datasets such as the National Lung Screening Trial in conjunction with locally collected datasets can help clinicians provide more personalized malignancy risk predictions and follow-up recommendations.
CONCLUSION: By incorporating 3 demographic data points, the risk of lung nodule malignancy within the Fleischner categories can be considerably stratified and more personalized follow-up recommendations can be made.
引用
- Hostetter JM, Morrison JJ, Morris M, et al. Personalizing lung cancer risk prediction and imaging follow-up recommendations using the National Lung Screening Trial dataset. J Am Med Inform Assoc. 2017. PMID: 28340104. doi:10.1093/jamia/ocx012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。